Workflow
易瑞转债
icon
Search documents
中证转债指数午盘上涨0.75%
Mei Ri Jing Ji Xin Wen· 2025-08-21 06:58
Group 1 - The Zhongzheng Convertible Bond Index rose by 0.75% to 485.73 points on August 21 [1] - Notable gainers included Dongshi Convertible Bond, Shuiyang Convertible Bond, Dayuan Convertible Bond, Sailong Convertible Bond, and Yirui Convertible Bond, with increases of 20.00%, 11.18%, 9.89%, 8.02%, and 7.47% respectively [1] - Significant decliners included Chongda Convertible Bond 2, Jintian Convertible Bond, Jinlun Convertible Bond, Linuo Convertible Bond, and Borui Convertible Bond, with decreases of 6.55%, 5.42%, 4.50%, 3.74%, and 3.38% respectively [1]
易瑞生物股价下跌2.01% 公司公告不提前赎回可转债
Jin Rong Jie· 2025-08-20 16:44
Group 1 - The stock price of Yirui Bio is reported at 13.15 yuan, down 2.01% from the previous trading day, with an intraday high of 13.46 yuan and a low of 12.96 yuan, and a trading volume of 114 million yuan [1] - Yirui Bio's main business includes food rapid testing, animal epidemic disease testing, and in vitro diagnostics, with food rapid testing accounting for over 90% of its business [1] - The company is associated with sectors such as chemical pharmaceuticals, smallpox virus prevention, and specialized and innovative enterprises [1] Group 2 - On August 20, Yirui Bio announced that the board decided not to redeem the "Yirui Convertible Bonds" early, and if redemption clauses are triggered again within the next three months, the company will still not exercise its redemption rights [1] - On the same day, the net inflow of main funds was 4.467 million yuan, while the cumulative net outflow of main funds over the past five days was 10.4952 million yuan [1]
易瑞生物:关于不提前赎回“易瑞转债”的公告
Zheng Quan Ri Bao· 2025-08-20 13:46
证券日报网讯 8月20日晚间,易瑞生物发布公告称,公司于2025年8月20日召开第三届董事会第十二次 会议,审议通过了《关于不提前赎回"易瑞转债"的议案》,董事会决定本次不行使"易瑞转债"的提前赎 回权利,不提前赎回"易瑞转债",且未来三个月内(自2025年8月21日至2025年11月20日)"易瑞转 债"再次触发有条件赎回条款时,公司均不行使提前赎回权利。自2025年11月21日起算,若"易瑞转 债"再次触发上述有条件赎回条款,届时董事会将另行召开会议决定是否行使"易瑞转债"的提前赎回权 利。 (文章来源:证券日报) ...
21日投资提示:中装转2复牌
集思录· 2025-08-20 13:41
Group 1 - The core viewpoint of the article highlights the significant financial performance of Muyuan Foods, reporting a net profit of 10.53 billion yuan in the first half of the year, representing a year-on-year increase of 1169.77% [1] - ST Zhongzhuang has received a court decision and appointed a restructuring manager, leading to the resumption of trading for its stocks and convertible bonds [1] - Several convertible bonds, including Yirui, Sailong, and Dongfeng, have announced that they will not be forcibly redeemed [1][2] Group 2 - The article provides a detailed table of convertible bonds, including their current prices, redemption prices, last trading dates, last conversion dates, conversion values, remaining scales, and the proportion of convertible bonds to the underlying stocks [4][6] - Specific convertible bonds such as Dayu, Puna, and Guanda are listed with their respective current prices and conversion values, indicating their market performance and potential investment opportunities [4][6]
易瑞生物:关于“易瑞转债”预计触发赎回条件的提示性公告
证券日报网讯 8月13日晚间,易瑞生物发布公告称,公司股票价格自2025年7月28日至2025年8月13日已 有10个交易日的收盘价格不低于"易瑞转债"当期转股价格8.87元/股的130%(即11.531元/股)。如后续 公司股票收盘价格继续不低于当期转股价格的130%,预计可能触发"易瑞转债"有条件赎回条款。根据 《深圳市易瑞生物技术股份有限公司创业板向不特定对象发行可转换公司债券募集说明书》中有条件赎 回条款的相关规定,届时公司董事会有权决定是否按照债券面值加当期应计利息的价格赎回全部或部分 未转股的"易瑞转债"。 (编辑 任世碧) ...
易瑞生物: 关于“易瑞转债”预计触发赎回条件的提示性公告
Zheng Quan Zhi Xing· 2025-08-13 10:13
证券代码:300942 证券简称:易瑞生物 公告编号:2025-046 (一)可转债发行情况 经中国证券监督管理委员会《关于同意深圳市易瑞生物技术股份有限公司向 不特定对象发行可转换公司债券注册的批复》(证监许可〔2023〕1447 号)同意 注册,公司于 2023 年 8 月 18 日向不特定对象发行可转债 3,281,967 张,每张面 值为人民币 100.00 元,发行总额为人民币 328,196,700 元,期限为 6 年。 (二)可转债上市情况 债券代码:123220 债券简称:易瑞转债 深圳市易瑞生物技术股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确和完整,没有虚假 记载、误导性陈述或重大遗漏。 特别提示: 深圳市易瑞生物技术股份有限公司(以下简称"公司")股票价格自 2025 年 当期转股价格 8.87 元/股的 130%(即 11.531 元/股)。如后续公司股票收盘价格 继续不低于当期转股价格的 130%,预计可能触发"易瑞转债"有条件赎回条款。 根据《深圳市易瑞生物技术股份有限公司创业板向不特定对象发行可转换公司债 券募集说明书》(以下简称"《募集说明书》")中有条件赎回 ...
易瑞生物: 关于“易瑞转债”2025年付息的公告
Zheng Quan Zhi Xing· 2025-08-11 16:16
特别提示: 瑞转债"(面值1,000.00元)派发利息为4.00元(含税)。 登记在册的全体"易瑞转债"持有人享有本次派发的利息,在付息债权登记日 前(包括付息债权登记日)申请转换成公司股票的可转债,公司不再向其持有 人支付本计息年度及以后计息年度的利息。 经中国证券监督管理委员会《关于同意深圳市易瑞生物技术股份有限公司 向不特定对象发行可转换公司债券注册的批复》(证监许可〔2023〕1447 号) 同意注册,公司于 2023 年 8 月 18 日向不特定对象发行可转换公司债券 期限为 6 年。经深圳证券交易所同意,本次可转换公司债券已于 2023 年 9 月 6 日起在深圳证券交易所挂牌交易,债券简称"易瑞转债",债券代码"123220" 。 根据《深圳市易瑞生物技术股份有限公司创业板向不特定对象发行可转换 公司债券募集说明书》(以下简称"《募集说明书》")和《深圳市易瑞生物 技术股份有限公司向不特定对象发行可转换公司债券上市公告书》的相关条款 规定,在"易瑞转债"的计息期内,每年付息一次,公司将于 2025 年 8 月 18 日(星期一)按面值支付第二年利息。现将付息有关事项公告如下: 证券代码:3009 ...
中证转债指数低开0.01%。天路转债、测绘转债涨近6%,塞力转债涨近4%,易瑞转债、聚隆转债涨超3%;大禹转债跌超3%,西子转债、柳工转2、丽岛转债等跌超1%。
news flash· 2025-07-24 01:31
Core Viewpoint - The China Convertible Bond Index opened lower by 0.01%, indicating a slight decline in the market sentiment towards convertible bonds [1] Group 1: Market Performance - Tianlu Convertible Bond and Surveying and Mapping Convertible Bond rose nearly 6%, showing strong performance among certain bonds [1] - Saili Convertible Bond increased by nearly 4%, reflecting positive investor interest [1] - Yirui Convertible Bond and Julong Convertible Bond both saw gains of over 3%, indicating a favorable trend [1] - Dayu Convertible Bond dropped by over 3%, suggesting some negative sentiment [1] - Xizi Convertible Bond, Liugong Convertible Bond, and Lidong Convertible Bond all fell by over 1%, highlighting a broader decline in certain bonds [1]
易瑞生物实控人拟减持 上市当年净利最高近2年扣非亏
Zhong Guo Jing Ji Wang· 2025-07-07 03:31
Core Viewpoint - The announcement details the planned share reduction by the controlling shareholder and actual controller of Yirui Biological, which is not expected to significantly impact the company's governance structure or control [1][2]. Group 1: Share Reduction Plan - Yirui (Hainan) Venture Capital Co., Ltd., the controlling shareholder, plans to reduce its holdings by up to 3,531,208 shares, representing 0.88% of the total share capital [1]. - The actual controller, Zhu Hai, intends to reduce his holdings by up to 7,521,390 shares, accounting for 1.87% of the total share capital [1]. - The total planned reduction by both parties does not exceed 3% of the company's total share capital, with specific limits on the number of shares that can be sold within a 90-day period [1]. Group 2: Company Background and Financials - Yirui Biological was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on February 9, 2021, with an initial issuance of 40.86 million shares at a price of 5.31 yuan per share, raising a total of 217 million yuan [2]. - The company has raised a total of 545 million yuan from two fundraising events, with the first round netting 175 million yuan after expenses [3][4]. - The net profit attributable to shareholders for the years 2021, 2022, 2023, and 2024 were 236.51 million yuan, 82.97 million yuan, -184.91 million yuan, and 17.12 million yuan, respectively [4][5]. Group 3: Financial Performance - In 2024, the company's operating revenue is projected to be 224.25 million yuan, a decrease of 11.75% from 2023 [5]. - The net profit attributable to shareholders is expected to increase by 109.26% in 2024, reaching 17.12 million yuan, compared to a loss of 184.91 million yuan in 2023 [5]. - The cash flow from operating activities showed a significant improvement, with a net cash flow of 34.26 million yuan in 2024, compared to a negative cash flow of -37.25 million yuan in 2023, marking a 191.97% increase [5].
易瑞生物实控人方减持套现883万元 2021年上市两募资
Zhong Guo Jing Ji Wang· 2025-06-09 03:41
Core Viewpoint - The share reduction plan by major shareholders of Yirui Biological has been completed, resulting in a total cash-out of approximately 8.83 million yuan from the sales of shares [1][2]. Shareholder Reduction Summary - Yirui Biological's major shareholders, Yidari and Yikairei, executed their share reduction plans, with Yidari reducing 411,200 shares (0.1025% of total shares) and Yikairei reducing 575,700 shares (0.1435% of total shares) [1][3]. - Yidari's share reduction occurred through concentrated bidding and block trading, with an average price of 9.33 yuan per share for 116,200 shares and 8.76 yuan per share for 295,000 shares [3]. - Yikairei's share reduction also involved concentrated bidding and block trading, with an average price of 9.30 yuan per share for 275,700 shares and 8.66 yuan per share for 300,000 shares [3]. Shareholder Equity Changes - Shareholder Wang Tianyi reduced his holdings by 6,337,700 shares (1.5792% of total shares) from April 25 to June 6, 2025, bringing his total holdings down to 20,065,821 shares (4.999984% of total shares) [2][4]. - Wang Tianyi's reduction means he is no longer a major shareholder with over 5% ownership [2][4]. Company Financial Activities - Yirui Biological raised a total of 217 million yuan during its IPO, with a net amount of 175 million yuan after deducting issuance costs [6]. - The company issued convertible bonds worth 328.2 million yuan in August 2023, which began trading on September 6, 2023 [7].